Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Atack

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Biopharmaceutics & Drug Disposition|June 16, 2007
Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligandsAndrew Pike, Susan M Cook, Alan P Watt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 14, 2006
Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomographyJohn R Atack, Paul Scott-Stevens, John S Beech, et al.
Journal of Psychopharmacology (Oxford, England)|November 27, 2019
Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profileSimon E Ward, Mark H Harries, Laura Aldegheri, et al.
Journal of Medicinal Chemistry|November 13, 2004
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing propertiesMark S Chambers, John R Atack, Robert W Carling, et al.
Biological Psychiatry|March 15, 2008
In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonistKoen Van Laere, Guy Bormans, Sandra M Sanabria-Bohórquez, et al.
Communications Biology|April 12, 2022
Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemaseChloe R Koulouris, Sian E Gardiner, Tessa K Harris, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2004
Tricyclic pyridones as functionally selective human GABAA alpha 2/3 receptor-ion channel ligandsJames Crawforth, John R Atack, Susan M Cook, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
British Journal of Pharmacology|January 6, 2026
A PK/PD study on antihyperalgesia by an α2/3-GABA<sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1-GABA<sub>A</sub> receptorsElena Neumann, Mariana O Popa, Karen T Elvers, et al.
Journal of Medicinal Chemistry|May 16, 2003
Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognitionMark S Chambers, John R Atack, Howard B Broughton, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Biopharmaceutics & Drug Disposition|June 16, 2007
Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligandsAndrew Pike, Susan M Cook, Alan P Watt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 14, 2006
Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomographyJohn R Atack, Paul Scott-Stevens, John S Beech, et al.
Journal of Psychopharmacology (Oxford, England)|November 27, 2019
Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profileSimon E Ward, Mark H Harries, Laura Aldegheri, et al.
Journal of Medicinal Chemistry|November 13, 2004
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing propertiesMark S Chambers, John R Atack, Robert W Carling, et al.
Biological Psychiatry|March 15, 2008
In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonistKoen Van Laere, Guy Bormans, Sandra M Sanabria-Bohórquez, et al.
Communications Biology|April 12, 2022
Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemaseChloe R Koulouris, Sian E Gardiner, Tessa K Harris, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2004
Tricyclic pyridones as functionally selective human GABAA alpha 2/3 receptor-ion channel ligandsJames Crawforth, John R Atack, Susan M Cook, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]Jonathan D Best, Mark T Jay, Franklin Otu, et al.
British Journal of Pharmacology|January 6, 2026
A PK/PD study on antihyperalgesia by an α2/3-GABA<sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1-GABA<sub>A</sub> receptorsElena Neumann, Mariana O Popa, Karen T Elvers, et al.
Journal of Medicinal Chemistry|May 16, 2003
Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognitionMark S Chambers, John R Atack, Howard B Broughton, et al.
Pageof 10